Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2CNS 2Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

cediranib 1carboxyamido-triazole 1capmatinib 1Thalidomide 1Paclitaxel 1Gefitinib 1Fluorodeoxyglucose F18 1Fentanyl 1FPP(RGD)2 1Everolimus 1Erlotinib Hydrochloride 1Docetaxel 1CLR1404 1Bevacizumab 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × capmatinib × Genitourinary × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡